Athira Pharma (ATHA) Reiterated at Buy by Stifel Despite Price Plunge, Cites $7 Cash per Share and Awaits Further Updates
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating on Athira Pharma (NASDAQ: ATHA), despite the failure of the company's ACT-AD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
